Publikasi Scopus 2024 per tanggal 30 September 2024 (820 artikel)

Nurkanto A.; Masrukhin; Erdian Tampubolon J.C.; Ewaldo M.F.; Putri A.L.; Ratnakomala S.; Setiawan R.; Fathoni A.; Palupi K.D.; Rahmawati Y.; Waluyo D.; Prabandari E.E.; Pujiyanto S.; Sumii Y.; Agusta A.; Shibata N.; Matsumoto S.; Nozaki T.
Nurkanto, Arif (36025675800); Masrukhin (57549264700); Erdian Tampubolon, Joseph Calvin (59144621000); Ewaldo, Muhammad Farrel (58945342800); Putri, Ade Lia (57209798664); Ratnakomala, Shanti (35107944600); Setiawan, Ruby (57211191838); Fathoni, Ahmad (57204041645); Palupi, Kartika Dyah (57219157281); Rahmawati, Yulia (57221416093); Waluyo, Danang (15746982100); Prabandari, Erwahyuni Endang (57200108452); Pujiyanto, Sri (55143898100); Sumii, Yuji (25823373000); Agusta, Andria (9740862300); Shiba
36025675800; 57549264700; 59144621000; 58945342800; 57209798664; 35107944600; 57211191838; 57204041645; 57219157281; 57221416093; 15746982100; 57200108452; 55143898100; 25823373000; 9740862300; 7202534160; 35414579600; 7202909217
Exploring Indonesian actinomycete extracts for anti-tubercular compounds: Integrating inhibition assessment, genomic analysis, and prediction of its target by molecular docking
2024
Heliyon
10
15
e35648
0
Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Biology, Faculty of Science and Mathematics, Diponegoro University, Central Java, Indonesia; Master's Programme in Biomedical Science, Faculty of Medicine, University of Indonesia, West Java, Indonesia; Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency (BRIN), West Java, Indonesia; Research Center for Vaccine and Drug, Research Organization for Health, National Research and Innovation Agency (BRIN), Banten, Indonesia; Department of Frontier Materials, Nagoya Institute of Technology, Nagoya, Japan; Department of Bacteriology, School of Medicine, Niigata University, Niigata, Japan; Laboratory of Tuberculosis, Institute of Tropical Disease, University of Airlangga, East Java, Surabaya, Indonesia; Division of Research Aids, Hokkaido University Institute for Vaccine Research & Development, Sapporo, Japan
Nurkanto A., Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia; Masrukhin, Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Erdian Tampubolon J.C., Department of Biology, Faculty of Science and Mathematics, Diponegoro University, Central Java, Indonesia; Ewaldo M.F., Master's Programme in Biomedical Science, Faculty of Medicine, University of Indonesia, West Java, Indonesia; Putri A.L., Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia; Ratnakomala S., Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia; Setiawan R., Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia; Fathoni A., Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency (BRIN), West Java, Indonesia; Palupi K.D., Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency (BRIN), West Java, Indonesia; Rahmawati Y., Research Center for Biosystematics and Evolution, Research Organization for Life Sciences and Environmental, National Research and Innovation Agency (BRIN), West Java, Indonesia; Waluyo D., Research Center for Vaccine and Drug, Research Organization for Health, National Research and Innovation Agency (BRIN), Banten, Indonesia; Prabandari E.E., Research Center for Vaccine and Drug, Research Organization for Health, National Research and Innovation Agency (BRIN), Banten, Indonesia; Pujiyanto S., Department of Biology, Faculty of Science and Mathematics, Diponegoro University, Central Java, Indonesia; Sumii Y., Department of Frontier Materials, Nagoya Institute of Technology, Nagoya, Japan; Agusta A., Research Center for Pharmaceutical Ingredients and Traditional Medicine, National Research and Innovation Agency (BRIN), West Java, Indonesia; Shibata N., Department of Frontier Materials, Nagoya Institute of Technology, Nagoya, Japan; Matsumoto S., Department of Bacteriology, School of Medicine, Niigata University, Niigata, Japan, Laboratory of Tuberculosis, Institute of Tropical Disease, University of Airlangga, East Java, Surabaya, Indonesia, Division of Research Aids, Hokkaido University Institute for Vaccine Research & Development, Sapporo, Japan; Nozaki T., Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Tuberculosis (TB) is the foremost cause of infectious fatality globally. The primary global challenge in combatting TB lies in addressing the emergence of drug-resistant variants of the disease. However, the number of newly approved agents for treating TB has remained remarkably low over recent decades. Hence, research endeavors for discovering novel anti-TB agents are always needed. In the present study, we screened over 1,500 culture extracts from actinomycetes isolated in Indonesia for their inhibitory activity against Mycobacterium smegmatis used as a surrogate in the primary screening. The initial screening yielded approximately 6.2 % hit extracts, with a selection criterion of >80 % growth inhibition. The confirmed hit extracts were subsequently subjected to growth inhibition assay against Mycobacterium bovis and Mycobacterium tuberculosis. Approximately 20 % of the hit extracts that showed growth inhibition also exhibited efficacy against M. bovis BCG and M. tuberculosis H37Rv pathogenic strain. An active compound was successfully purified from a large-scale culture of the most potent representative extract by high-performance liquid chromatography and thin-layer chromatography. The structure of the active compound was elucidated by mass spectrometry and nuclear magnetic resonance. This compound displayed structural similarities to actinomycin group and exhibited robust inhibition, with IC50 values of 0.74, 0.02, and 0.07 μg/mL against M. smegmatis, M. bovis, and M. tuberculosis, respectively. The Actinomycetes strain A612, which produced the active compound, was taxonomically classified by phylogenetic analysis of 16s rRNA gene and whole genome sequencing data as Streptomyces parvus. Computational genome analysis utilizing anti-SMASH 7.0 unveiled that S. parvus A612 strain harbors 40 biosynthetic gene clusters with the potential to produce 16 known (with >70 % similarity) and 24 unknown compounds. A non-ribosomal peptide synthesis (NRPS) gene cluster associated with actinomycin D biosynthesis was also identified, boasting an 85 % similarity. Molecular docking analysis of actinomycin D and 21 potential M. tuberculosis targets revealed possible interactions with multiple targets. The purified active compound inhibited recombinant M. tuberculosis shikimate kinase (MtSK), which validated the results obtained from the docking analysis. © 2024 The Author(s)
Actinomycetes; Active compound; Docking study; Extracts; Screening; Shikimate kinase; Tuberculosis; Whole genome
Japan Agency for Medical Research and Development, AMED; Japan International Cooperation Agency, JICA; Science and Technology Research Partnership for Sustainable Development, SATREPS; Priority grant of Drug and Vaccine by Research Organization for Health BRIN; Reset Inovasi Untuk Indonesia Maju, Rispro LPDP Indonesia, (RIIM-B-803/II.7.5/FR/6/2022, B-1373/III.5/PR.03.08/6/2022)
This work was supported in part by a grant from Reset Inovasi Untuk Indonesia Maju, Rispro LPDP Indonesia (RIIM-B-803/II.7.5/FR/6/2022 and B-1373/III.5/PR.03.08/6/2022) and Priority grant of Drug and Vaccine by Research Organization for Health BRIN (DIPA). This research was also supported by Science and Technology Research Partnership for Sustainable Development (SATREPS) from the Japan Agency for
Elsevier Ltd
24058440
Article
Q1
617
8649